Skip to main content

Advertisement

SpringerLink
Log in

Short or Long Survival in Multiple Myeloma. A Simple Method for Determining the Prognosis

  • Original Paper
  • Published:
Pathology & Oncology Research

Abstract

Finding prognostic factors in multiple myeloma is a real challenge. Several attempts might be found in the literature for that purpose but the results are not satisfactory. Therefore, in the current retorpective study authors analyzed the potential prognostic value of some laboratory data in 104 patients with multiple myeloma. They found the albumin and M-component ratio being lower than 1 and the initial WBC <4,5 × 109/l correlated strongly with poor prognosis. In addition the low albumin level was not related to albuminuria and that the low WBC was not linked to bone marrow infiltration rate or to antineutrophil antibody formation. On the basis of their experiences authors created an AMWBC score containing A/M and WBC at diagnosis found to be in good correlation to prognosis. Further studies involving more patients are needed to verify the real prognostic value of AMWBC score in multiple myeloma treated with new targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Attal M, Harorusseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. NEJM 335:9–7

    Article  Google Scholar 

  2. Kyle RA (1983) Long term survival in multiple myeloma. NEJM 308:314–316

    CAS  PubMed  Google Scholar 

  3. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 38:842–854

    Article  Google Scholar 

  4. Greipp PR, Witzig TE, Gonchoroff NJ (1985) Immunofluorescent plasma cell labeling indices (Li) using a monoclonal antibody (Bu-1). Am J Hematol 20:289

    Article  CAS  PubMed  Google Scholar 

  5. Sipos A, Csortos C, Sipka S et al (1998) The antigen/receptor specificity of antigegranulocyte antibodies in patients with SLE. Immunol Letters 19:329–334

    Article  Google Scholar 

  6. Ershler WB, Keller ET (2000) Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51:245–270

    Article  CAS  PubMed  Google Scholar 

  7. Gautier M, Robertson J, Hars V (1997) Prognostic factors in survival for patients with multiple myeloma from a single institution over 30 years. Blood 90:/10S1/A 4089

  8. Fassa ABT, Spencer T, Sawyer J et al (2002) Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Brit J Haematol 118:1041–1047

    Article  Google Scholar 

  9. Jacobson JL, Hussein MA, Barlogie B et al (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Brit J Haematol 122:441–450

    Article  Google Scholar 

  10. Bladé J, Rozman C, Cervantes F et al (1989) A new prognostic system for multiple myeloma based on easily available parameters. Brit J Haematol 72:507–511

    Article  Google Scholar 

  11. Symeonidis A, Kouraklis-Symeonidis A, Grouzi E et al (2002) Determination of Plasma cell screening potential as an index of maturity myelomatous cell and a strong prognostic factor. Leukemia Lymphoma 43:1605–1612

    Article  CAS  PubMed  Google Scholar 

  12. Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33

    Article  PubMed  Google Scholar 

  13. Greipp PR, Miguel JS, Durie BGM et al (2005) International staging system for multiple myeloma. JCO 23:3412–3420

    Article  Google Scholar 

  14. Mori M, Abe T, Takei T et al (1992) The significance of myelodysplasia in untreated patients with multiple myeloma. Rhinosho-Keutsueki 33:662–665

    CAS  Google Scholar 

  15. Coppelstone JA, Mufti GJ, Hamblin TJ et al (1986) Immunological abnormalities in myelodysplastic syndromes. Brit J Haematol 63:149–159

    Article  Google Scholar 

  16. Hus I, Dmoszynska A, Manko J et al (2004) An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Brit J Cancer 91:1873–1879

    Article  CAS  PubMed  Google Scholar 

  17. Anagnostopoulos A, Zervas K, Zomas A et al (2003) The international prognostic index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide–based regimens. Blood 937A:3492

    Google Scholar 

Download references

Acknowledgement

Authors grateful to professor Moshe Mitelman who advised us to check antineutrophil antibodies.

Author information

Authors and Affiliations

  1. 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4., 1125, Budapest, Hungary

    Judit Várkonyi, Edina Bajzik, Ádám Fazakas & István Karádi

  2. 3rd Department of Medicine, University Medical School of Debrecen, Debrecen, Hungary

    Sándor Sipka

Authors
  1. Judit Várkonyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edina Bajzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ádám Fazakas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sándor Sipka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. István Karádi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Judit Várkonyi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Várkonyi, J., Bajzik, E., Fazakas, Á. et al. Short or Long Survival in Multiple Myeloma. A Simple Method for Determining the Prognosis. Pathol. Oncol. Res. 15, 383–387 (2009). https://doi.org/10.1007/s12253-008-9134-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-008-9134-9

Keywords

Search

Navigation